Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Interpersonal Functioning & Social Connectedness

Psilocybin for Interpersonal Functioning & Social Connectedness

43 papers and 12 clinical trials exploring psilocybin as a treatment for interpersonal functioning & social connectedness.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 300 million individuals worldwide experience issues with social connectedness and interpersonal relations.

Interpersonal Functioning & Social Connectedness

Research on psychedelics highlights their potential to enhance interpersonal functioning and social connectedness, particularly through compounds such as psilocybin and MDMA. These compounds may facilitate therapeutic outcomes in various mental health disorders by fostering emotional connectivity and empathy among individuals.

Full Interpersonal Functioning & Social Connectedness profile

Academic Research

43 papers
Paywallindividual

Cognitive and Subjective Effects of Psilocybin Microdosing: Results from Two Double-Blind Placebo-Controlled Longitudinal Trials

This set of two randomised, double-blind, placebo-controlled trials (n=141) investigated the longitudinal effects of microdosing psilocybin truffles on cognition and well-being in semi-naturalistic settings. Contrary to anecdotal reports, the study finds no significant improvements in cognitive control, memory, social cognition, or subjective well-being compared with placebo.

Published
February 1, 2026
Journal
Neuropharmacology
Authors
Prochazkova, L., Marschall, J., Lippelt, D. P., Schon, N. R., Kuchař, M., Hommel, B.
Open Accessindividual

Psilocybin increases emotional empathy in patients with major depression

In a randomized, placebo-controlled trial of 51 patients with major depression, a single dose of psilocybin (0.215 mg/kg) given alongside a four-week psychological support intervention produced significant increases in explicit emotional empathy—especially towards positive stimuli—relative to placebo that persisted for at least two weeks. The findings indicate that psychedelics can enhance social cognition in depression and may contribute to their therapeutic effects.

Published
December 18, 2024
Journal
Molecular Psychiatry
Authors
Jungwirth, J., Von Rotz, R., Dziobek, I., Vollenweider, F. X., Preller, K. H.
Paywallindividual

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

This technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.

Published
December 1, 2024
Journal
Psychedelic Medicine
Authors
Back, A., Myers, S., Guy, J., Perez, J., Thorn, L. L., Mcgregor, B.
Open Accessmeta

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task

This meta-analysis (s=5, n=158) of classic psychedelic effects on empathy using the Multifaceted Empathy Test (MET) finds significant enhancement of explicit and implicit emotional empathy, with no effect on cognitive empathy. The analysis covers studies up to November 2023 examining LSD, psilocybin, and ayahuasca.

Published
October 18, 2024
Journal
Scientific Reports
Authors
Olami, A., Peled-Avron, L.
Paywallindividual

Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

This online survey (n=233) of autistic participants with high autism quotient scores examines their experiences with psychedelic drugs and perceived changes attributed to their most 'impactful' psychedelic experience. It finds that the majority of participants reported reductions in psychological distress (82%) and social anxiety (78%), and increases in social engagement (70%), while 20% reported undesirable effects such as increased anxiety.

Published
October 5, 2024
Journal
Psychopharmacology
Authors
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., Kamboj, S. K.
Open Accessindividual

Effects of Psychedelic Microdosing versus Conventional ADHD Medication Use on Emotion Regulation, Empathy, and ADHD Symptoms in Adults with severe ADHD symptoms: A Naturalistic Prospective Comparison Study

Two naturalistic prospective studies in adults with severe ADHD symptoms found that psychedelic microdosing was associated with improved emotion regulation and a reduction in ADHD symptom severity over four weeks, with a persistent benefit on expressive suppression when compared with controls and conventional medication. There was no robust evidence that microdosing improved empathy.

Published
February 14, 2024
Journal
European Psychiatry
Authors
Haijen, E. C. H. M., Hurks, P. P. M., Kuypers, K. P. C.

Clinical Trials

12 trials
Not yet recruitingPhase II

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (PsiPTSD)

This quadruple-blind, randomised controlled trial (n=76) will study the effects of psilocybin (25mg or 1mg) combined with Acceptance and Commitment Therapy (ACT) in adult survivors of intimate partner violence (IPV) with post-traumatic stress disorder (PTSD).

Started
August 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06885996
Not yet recruitingPhase II

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer (PEARL-C1)

This Phase II open-label trial (n=15) will study the effects of psilocybin (25 mg) administered in the context of Psilocybin-assisted Existential, Attachment and Relational (PEARL) therapy for caregivers of patients with advanced cancer.

Started
July 2, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07048743
RecruitingPhase I/II

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

Open-label single-group study (n=10) assessing feasibility, safety, and preliminary efficacy of a single 25 mg oral psilocybin dose with preparatory and integration therapy for UCSD physicians with burnout.

Started
April 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06814522
RecruitingPhase II

Investigation to Understand and Optimize Psilocybin (OPTIMIZE)

This interventional trial (n=141) will investigate whether transcutaneous auricular VNS (taVNS) after a single 25 mg psilocybin dose enhances antidepressant effects in adults with major depressive episodes.

Started
February 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06512194
RecruitingPhase I

Psilocybin for Prolonged Grief Disorder

Open-label, single-arm early-phase I study (n=12) testing a single 25 mg oral dose of psilocybin for individuals with prolonged grief disorder to assess feasibility and symptom change.

Started
February 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06724289
RecruitingPhase I/II

Psychedelic-assisted Group Program for First Responders

This interventional feasibility study (n=32) will evaluate the impact of oral psilocybin (10mg) combined with a 12-week group-based programme tailored for firefighters.

Started
January 1, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06471959

Explore further

Search all Psilocybin papers Search all Interpersonal Functioning & Social Connectedness trials Full Psilocybin profile Full Interpersonal Functioning & Social Connectedness profile